IOL CHEM AND PHARMA LTD
IOLCP · General/Diversified · NSE
₹130
Current Market Price
Fair Value (DCF)
₹98
Discount to FV
-24.5%
Updated just now
YieldIQ Score
54/100
Piotroski F-Score
6/9
Economic Moat
None
Confidence
62%
ROE
7.7%
Debt/Equity
0.08
WACC
11.1%
Market Cap
₹3,802 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.4%
Return on capital employed
EV / EBITDA
7.9×
Enterprise multiple
Debt / EBITDA
0.5×
Leverage vs earnings
Interest Coverage
14.9×
EBIT covers interest
Current Ratio
1.89×
Short-term liquidity
Asset Turnover
0.92×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹129.54
Bear case
Discount -119.7%
Base case
Discount -32.4%
Bull case
Discount -6.5%
Ratio Trends
IOLCP · last 9 annual periods
ROE
7.7%
ROCE
14.4%
Operating Margin
—
Debt / Equity
0.08×
PE
15.5×
EV / EBITDA
7.9×
Historical Financials
IOLCP · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2168 Cr | ₹2202 Cr | ₹2119 Cr | ₹2079 Cr | ₹2319 Cr | +1.7% |
| EBITDA | ₹271 Cr | ₹246 Cr | ₹255 Cr | ₹225 Cr | ₹279 Cr | +0.8% |
| EBIT | ₹233 Cr | ₹205 Cr | ₹198 Cr | — | — | -4.0% |
| PAT | ₹168 Cr | ₹139 Cr | ₹134 Cr | ₹101 Cr | ₹138 Cr | -4.8% |
| EPS (diluted) | ₹28.56 | ₹23.70 | ₹22.90 | — | — | -5.4% |
| CFO | ₹93.0 Cr | ₹122 Cr | ₹290 Cr | ₹179 Cr | ₹214 Cr | +23.2% |
| CapEx | ₹-153 Cr | ₹-212 Cr | ₹-274 Cr | ₹-214 Cr | ₹-173 Cr | — |
| FCF | ₹-60.2 Cr | ₹-89.5 Cr | ₹15.6 Cr | ₹-34.9 Cr | ₹41.3 Cr | — |
| Total Assets | ₹1962 Cr | ₹2022 Cr | ₹2244 Cr | ₹2382 Cr | ₹2587 Cr | +7.2% |
| Total Debt | ₹44.0 Cr | ₹79.8 Cr | ₹32.8 Cr | ₹117 Cr | ₹135 Cr | +32.5% |
| Shareholders' Equity | ₹1392 Cr | ₹1508 Cr | ₹1612 Cr | ₹1688 Cr | ₹1799 Cr | +6.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
IOLCP vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
BLISSGVS BLISSGVS | — | — | Pending | 10.8% | 17.7× |
 ORCHPHARMA ORCHPHARMA | — | — | Pending | 7.9% | — |
 UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
SOLARA SOLARA | — | — | Pending | 0.0% | — |
 GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
8 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹4.80/sh
Last payout
2026-02-17
₹1.00
Peak payout
₹1.00
Trailing yield
0.77%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. IOL CHEM AND PHARMA LTD (IOLCP.NS) trades at 129.54 vs a model fair value of 97.81, a gap of -24.5%. Piotroski F-score: 6/9. Moat label: ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of IOLCP →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for IOLCP →
Compare
Head-to-head with peers
Compare IOLCP side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse IOLCPNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.